ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Regenxbio Inc. (RGNX) on Thursday reported a loss of $51.2 million in its fourth quarter.
On a per-share basis, the Rockville, Maryland-based company said it had a loss of $1.01.
The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.27 per share.
The biotechnology company posted revenue of $21.2 million in the period, falling short of Street forecasts. Five analysts surveyed by Zacks expected $22.9 million.
For the year, the company reported a loss of $227.1 million, or $4.59 per share. Revenue was reported as $83.3 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RGNX at https://www.zacks.com/ap/RGNX
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。